The stem cell transplantation is emerging as a potential therapeutic modality for patients with heart failure. It has been demonstrated that intracoronary stem cell transplantation had beneficial effects on left ventricular perfusion and contractile functions. We hypothesized that patients with end-stage ischemic cardiomyopathy, who are candidates for heart transplantation, could also benefit from autologous intracoronary stem cell transplantation. We performed a prospective, openlabeled study in 10 patients with end-stage ischemic cardiomyopathy, who were on the waiting list for heart transplantation. Each patient received bone marrow-derived mononuclear cell infusion via balloon catheter in the target vessel, which had been revascularized by percutaneous intervention and was patent before the procedure. Clinical and laboratory evaluations, a treadmill exercise test, echocardiography, and single photon emission tomography (SPECT) were performed to the patients at baseline and 6 months after stem cell infusion. At 6-month follow-up of the eight patients who were able to complete the study, we revealed a significant increase in ejection fraction (from 30.0 ± 6.6% to 36.2 ± 7.3%; p = 0.001) in echocardiographic evaluation. SPECT evaluation also displayed a reduction in infarct area (50.4 ± 16.1% to 44.1 ± 12.5%; p = 0.003). Both myocardial oxygen consumption ( p = 0.001) and metabolic equivalents ( p = 0.001) were significantly increased at 6-month follow-up. These results demonstrate that intracoronary stem cell transplantation ameliorates heart failure symptoms and improves left ventricular function and perfusion. Therefore intracoronary stem cell transplantation may be used as an alternative treatment option for heart transplant candidates. cellular cardiomyoplasty; heart transplant candidates; intracoronary infusion; stem cells; ischemic cardiomyopathy
dyskinesia of the anterior wall and a non-obstructed infarct releated artery, which was patent for at least 6 months prior to stem cell therapy was mandatory for inclusion. Patients were required to be in stable clinical conditions under maximally tolerated medical therapy including angiotensine converting enzyme (ACE) inhibitors, beta-blockers and diuretics.
Exclusion criteria were difficulty in obtaining vascular access for percutaneous procedures; abnormal hemoglobin, platelet or leukocyte counts, conditions that may adversely affect bone marrow (such as malignancy, chronic infections, primary hematologic diseases or HIV), significant ventricular dysrhythmias (sustained ventricular tachycardia, atrial fibrillation), acute MI within the previous 6 months and hemodynamic instability.
This non-randomised, open-labeled clinical study was approved by the Ethics Commitee of our institute and written informed consent was obtained from each patient. The study have carried out according to the Declaration of Helsinki.
Study protocol
Baseline evaluations. Baseline evaluations included laboratory evaluations (complete blood count, high sensitive C-reactive protein [hsCRP] , serum creatinine and cardiac specific enzymes; troponin T, creatinine kinase-MB), exercise stress single photon emission tomography (SPECT) perfusion scanning with ramp treadmil protocol (Gibbons et al. 2002) , 2D and Doppler echocardiography, coronary angiography (Fig. 1) . Additionally, laboratory evaluations were repeated 24 hrs after the procedure.
Bone marrow aspiration and isolation of bonemarrow derived stem cells. We used autologous bonemarrow derived mononuclear cells (BMC) in this study. Bone marrow (40 ml) was aspirated under local anesthesia from posterior illiac crest of patients. We used the same technique for isolation of BMCs as previously described by Strauer et al. (2001) . Briefly, mononuclear BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium (Ficoll-Paque Plus, Amersham Biosciences, UK). Three washing steps were performed and cells were resuspended in heparinized saline for use. Tryphan Blue was used for testing viability (exclusion method) and showed a viability of more than 90% of cells for each transplantion and the mean amount of the mononuclear cells was 3.6 ± 0.2 × 10 7 . Repeated microbiological test of the cell suspensions taken prior to transplantation were negative for including percutaneous interventions (PCI) and coronary artery bypass grafting, may enable to survive cardiomyocytes, which causes fibrous akinetic myocardial tissue formation that might lead to the left ventricular remodelling, aneurysm formation and progression to CHF. Therefore a growing number of patients with coronary artery disease progress to end-stage heart failure, which is a well accepted progressive disease with high mortality and morbidity rates (Ho et al. 1993) . Cardiac transplantation may be considered as an alternative treatment option in this group of patients despite the problems led by the organ shortage and the expected postoperative complications. Recently, many experimental cellular cardiomyoplasty studies demonstrated the potential effect of stem cell transplantation on the left ventricular perfusion and contractile function when transplantated to the damaged heart (Asahara et al. 1999; Satomi-Kobayashi et al. 2002) . Further evidence from clinical studies also marked beneficial effects of intracoronary infusion of stem cells in postinfarction period (Asahara et al. 1999; Assmus et al. 2002; Strauer et al. 2002; Stamm et al. 2003; Wollert et al. 2004) . Both transendocardial delivery (Fuchs et al. 2003; Perin et al. 2003) and transepicardial direct injections (Hamano et al. 2001; Tse et al. 2003) of stem cells were reported as safe and feasible in coronary artery disease patients with no mechanical revascularization option. These results support the proposal of intracoronary stem cell infusion as an alternative therapy for heart transplant candidates waiting for a donor heart.
In this study, our objective was to evaluate the safety and feasibility of intracoronary infusion of stem cell in heart transplant candidates.
METHODS

Study patients
We prospectively enrolled 10 patients with severe ischemic heart failure with no remaining option for standard revascularization and candidates for heart transplantation. All patients had exprienced acute MI and revascularized by PCI on avarage of 3.5 ± 1.4 years before being included in the study. Additionally, an akinesia or each transplant.
Intracoronary transplantation of stem cells. Following baseline evaluations, patients were taken to the cardiac catheterization laboratory approximately one hr before the anticipated arrival of the BMCs from the hematology laboratory. The BMC suspension (10 ml) was infused into infarct-related artery via the central lumen of a 3-mm over-the-wire balloon catheter (Occam International, Eindhoven, Netherlands).
Aiming to interrupt antegrade blood flow during cell infusion, the balloon was inflated inside the stented segment of the coronary artery at low pressures (2-4 atm) for 3-4 min. The inflation time was prolonged for 1-2 min after the infusion completed, to allow maximum contact time with the microcirculation. After completion of intracoronary cell infusion, coronary angiography was repeated to obtain vessel patency.
6-month follow-up evaluations. Six months after catheter-based stem cell transplantation, all functional assessment tests (laboratory evaluation, exercise stress SPECT, echocardiography and coronary angiography) were repeated. Bruce protocol was modified to two 3-min warm-up stages at 1.7 mph, with 0 percent slope and 1.7 mph, with 5% slope due to patients' limited exercise capacity affected by end-stage heart failure (Fletcher et al. 2001) . The echocardiographic data were analyzed by 2 independent, blinded, exprienced observers. Digitally stored images were analyzed offline. Left ventricular end-systolic volume (LVESV), end-diastolic volume (LVEDV) and ejection fractions (EF) were measured according to the standard protocols.
We performed exercise stress single photon emission tomography (SPECT) imaging with the same procedure, at baseline and follow-up. Technetium-99m Tetraphosmine (8 mCi) was injected after stress, followed by another injection of 22 mCi Technetium-99m Tetraphosmine in approximately 2-3 hrs. Acquisitions were performed with a two-detector gamma camera (ADAC Vertex), acquiring 32 projections over 180° (right anterior oblique 45° to left posterior oblique 45° and low-energy high-resolution collimation; 64 × 64 matrixes, and 50 sec for stress and 40 sec for resting images). Short axis and vertical and horizontal long-axis sections of the left ventricle were extracted from the recontructed Fig. 1 . Study protocol. Ten patients with severe ischemic heart failure who were on the waiting list for heart transplantation enrolled the study. After performing baseline evaluations, they underwent coronary catheterization and intracoronary stem cell infusion therapy. Eight patients completed the study while 2 patients died during the 6-month follow-up period.
analysis. Quantitative gated and Bull's eye SPECT analyses were performed on an ICON workstation computer. Rest defect was calculated by Bull's Eye analysis in percentages and results were compared to follow-up outcomes.
Statistical analysis
We used SPSS V 12.0 (Statistical Package for the Social Sciencies INC., Chicago, IL, USA) for statistical analysis. The values of the continuous variables were presented as means and standard deviations, categorical variables were presented as percentages. For matching series student's t-test was used for comparing parametrical outcomes. Paired sample analysis were used to compare the 2 time points (baseline vs 6 months). P 0.05 was considered statistically significant. We used "Chisquare" test to compare non parametric outcomes.
RESULTS
Baseline characteristics
The demographic, clinical and angiographic characteristics of the study population are summarized in Table 1 . During the course, all patients underwent maximal tolerated medical therapy for heart failure. During the follow-up period, 2 mortalities occurred: one developed cardiac arrest at 2 months and one with the the lowest ejection fraction (15%) in the study population developed decompansated heart failure and cardiogenic shock leading to death at 3 months. Thus, the 8 patients who could complete the study were evaluated.
Safety data
No major periprocedural complications or hospital events related with the stem cell therapy were reported (Table 2) . Also, no significant arrhythmia associated with the coronary infusion procedure occurred during the hospitalization period. All patients were discharged at the 3th No in hospital events observed during the 6 days after the procedure. However one of the patients was died by decompansated heart failure complicated by cardiogenic shock at 3 months while another one developped anterior reinfarction and was died 2 months after the procedure. MI, myocardial infarction; PCI, percutaneous intervention.
day after procedure. There was not any inflamatory response (white blood cell, hsCRP, troponin T) after the cell therapy immideately or at 6 months (Table 3 ). During the 6-month follow-up, two patients died and excluded from the study. One patient developed restenosis in infarct related artery which was successfully revascularized. The other 7 patients had good patency rates after the stem cell therapy.
6-Month follow-up evaluations
At 6-month follow-up echocardiography, significant improvements in ejection fractions were observed (from 30.0 ± 6.6% to 36.2 ± 7.3%; p = 0.001) ( Fig. 2A) although the improvement in LVEDV (191.2 ± 66.4 ml to 189.6 ± 63.5 ml; p = 0.248) and LVESV (130.7 ± 53.9 ml to 130.01 ± 52.9 ml; p = 0.607) were not statistically significant (Table 4) . Nuclear perfusion imaging studies assessed by Bull's Eye analysis showed significant reductions in infarct area (50.4 ± 16.1% to 44.1 ± 12.5%; p = 0.003) at 6 months (Fig. 2B) .
When the clinical performance in two time points as baseline and 6 months were compared, significant improvements in both myocardial volume oxygen consumption (11.8 ± 2.6 to 16.6 ± 2.5 ml/kg/min, p = 0.001) and metabolic equivalents (3.4 ± 0.7 to 4.8 ± 0.7, p = 0.001) were observed which, support higher work load (Table 4) .
DISCUSSION
The treatment options in patients with severe ischemic heart failure are limited to non-pharmacological interventions including cardiac assist device, ventricular resynchronization therapy, myocardial left ventricular resection for restoring ventricular geometry and mitral valve repair Fig. 2 . Illustration shows the mean values of (A) ejection fraction evaluated by 2D echocardiography and (B) % of infarct area calculated by Bull's Eye Analysis by SPECT at baseline (0) and 6-month follow-up (6). Note the significant improvement in ejection fraction and decrease in infarct size at 6-month follow-up.
A B techniques (Gregoric et al. 2002; Hare 2002) . Generally, these therapies aim to reduce systolic wall stress and myocardial oxygen consumption. Cardiac transplantation is an option for these group of patients, but the limited supply of donors creates the major drawback of the therapy rather than its efficacy or safety. Therefore alternative therapy options are necessary for heart transplant candidates. Silva et al. (2004) demonstrated for the first time that cellular cardiomyoplasty could be safe and feasible for patients listed for heart transplantation. They studied five heart transplant candidates and performed BMCs by transendocardial delivery method. The study resulted in improved exercise capacity among the study population. Supporting the study's outcomes, we demonstrated for the first time that intracoronary infusion of autologous BMC is also safe and feasible in heart transplant candidates. Furthermore our results suggested that BMC transplantation using intracoronary delivery method enhances exercise capacity along with improved left ventricular ejection fraction and perfusion of patients with end-stage congestive heart failure.
Stem cells are known to have beneficial effects on myocardial perfusion and left ventricular functions (Kocher et al. 2001; . Exciting results of the experimental studies have led to clinical studies which demonstrated benefit of the stem cells on left ventricular functions after acute myocardial infarction or ischemic cardiomyopathy (Chachques et al. 2004; Schuster et al. 2004; Ince et al. 2005) . Being accepted as an effective and safe way of performing stem cells into infarcted myocardial region, intracoronary infusion has become a preferable route in particularly acute MI patients (Chen et al. 2004; Fernandez-Aviles et al. 2004) .
There also exist a few studies done by using intracoronary infusion method in ischemic cardiomyopathy patients (Kuethe et al. 2005; Assmus et al. 2007 ). Cell retention might be expected to be limited after intracoronary delivery into chronically infarcted myocardium, due to the limited blood supply faced by transplanted cells or the environmental factors that affect homing or transdifferentiating into vascular cells and cardiomyocytes. Notwithstanding, transendocardial route of delivery offers a theoretical advantage over surgical and intracoronary approaches in chronic ischemic heart failure, because the viability of target site can be determined before each injection. However, Strauer et al. (2005) recently demonstrated that intracoronary infusion of BMC reduced infarct size and improved left ventricular functions in patients with chronic infarction.
Although there is still much to learn about the regenerative potential of transplanted BMCs, experimental studies suggest three possibilities of stem cells efficacy as new vessel formation, new myocardial formation and paracrine effects. Recently, researchers observed that BMCs were poorly trans-differentiated in cardiomyocytes and most of these cells were differentiated along the hematopoietic lineage (Murry et al. 2004) . But engraftment of hematopoietic cells in the infarct region could provide an improvement in cardiac functions (Balsam et al. 2004) . Recent suggestions affirm that BMCs are mainly shown to function by secreting some angiogenic ligands which provide improvement in neovascularization and regional blood flow (Kamihata et al. 2001; Kawamoto et al. 2003) . Despite the lack of further revascularization options, patients who are candidates for cardiac transplantation may still have a considerable amount of viable myocardium. Patients with severe heart failure with large segments of reversibly dysfunctional but viable myocardium are likely to have a significantly better prognosis after reperfusion (Lytle 2003) . Theroretically, usage of angiogenesis to improve perfusion of viable areas could be effective in this desperate patient population.
Among our study population, all patients had prior myocardial infarction, no other revascularization treatment options and severe symptoms of ischemia that consistently limited routine activity. They were in the waiting list for heart transplantation, with a mean myocardinal oxygen consumption (VO 2 ) of < 14 ml/kg/min and had compromised LV function (mean ejection fraction (EF) = 30%). At 6-month follow-up, we observed a significant increase in mVO 2 and metabolic equivalents (METS) of the patients in exercise stress testing ( p = 0.001). Besides, 5 of the 8 study patients who completed the 6-month follow-up period had mVO2 improved (mVO 2 > 14 ml/kg/ min) to a level that they no longer required cardiac transplantation. Restoration in exercise capacity is also related to a better quality of life.
In this safety and feasibility study we represent the intracoronary bone marrow-derived mononuclear cell transplantation as an alternative therapy in cardiac transplant candidates. The limitations of the study are the small number of the study population and the need for a control group. With the fact that the mortality rates approach to 50% per year among patients with severe heart failure and the limited source of donors for heart transplantation, we suggest that stem cell therapy may be used as an alternative therapeutic option for this group of patients.
